These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28738160)

  • 1. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation: Therapeutic potential of atrial K
    Ravens U; Odening KE
    Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atria-selective antiarrhythmic drugs in need of alliance partners.
    Peyronnet R; Ravens U
    Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial-Selective Potassium Channel Blockers.
    Voigt N; Dobrev D
    Card Electrophysiol Clin; 2016 Jun; 8(2):411-21. PubMed ID: 27261831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of cardiac potassium channels.
    Li GR; Dong MQ
    Adv Pharmacol; 2010; 59():93-134. PubMed ID: 20933200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.
    Voigt N; Rozmaritsa N; Trausch A; Zimniak T; Christ T; Wettwer E; Matschke K; Dobrev D; Ravens U
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):251-9. PubMed ID: 19760273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
    McEwen DP; Martens JR
    Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic Mechanisms of SK Channel Inhibition in the Rat Atrium.
    Skibsbye L; Wang X; Axelsen LN; Bomholtz SH; Nielsen MS; Grunnet M; Bentzen BH; Jespersen T
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):165-76. PubMed ID: 25856531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation.
    Machida T; Hashimoto N; Kuwahara I; Ogino Y; Matsuura J; Yamamoto W; Itano Y; Zamma A; Matsumoto R; Kamon J; Kobayashi T; Ishiwata N; Yamashita T; Ogura T; Nakaya H
    Circ Arrhythm Electrophysiol; 2011 Feb; 4(1):94-102. PubMed ID: 21156770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate-Dependent Role of I
    Aguilar M; Feng J; Vigmond E; Comtois P; Nattel S
    Biophys J; 2017 May; 112(9):1997-2010. PubMed ID: 28494969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cardiac potassium channels for state-of-the-art drug discovery.
    Walsh KB
    Expert Opin Drug Discov; 2015 Feb; 10(2):157-69. PubMed ID: 25400064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of the muscarinic potassium current by KB130015, a new antiarrhythmic agent to treat atrial fibrillation].
    Borchard R; van Bracht M; Wickenbrock I; Prull MW; Pott L; Trappe HJ
    Med Klin (Munich); 2005 Nov; 100(11):697-703. PubMed ID: 16328176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial selectivity of antiarrhythmic drugs.
    Ravens U; Poulet C; Wettwer E; Knaut M
    J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of I
    Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revealing kinetics and state-dependent binding properties of I
    Ellinwood N; Dobrev D; Morotti S; Grandi E
    Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical possibilities for the development of novel antiarrhythmic drugs.
    Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.